Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Rotate Klow Injection Sites: Peptide Type Comparison

GLP-1 Agonists (Semaglutide, Tirzepatide) 4–6mm Abdomen, thighs 7 days Low (±12%) Weekly dosing allows 4-site rotation per month; abdomen preferred for consistent pharmacokinetics Growth Hormone Secretagogues (GHRP-2, MK-677) 6mm Abdomen, thighs, arms 5–7 days

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • GLP-1 Agonists (Semaglutide, Tirzepatide)
  • 4–6mm
  • Abdomen, thighs
  • 7 days
  • Low (±12%)
  • Weekly dosing allows 4-site rotation per month; abdomen preferred for consistent pharmacokinetics
  • Growth Hormone Secretagogues (GHRP-2, MK-677)
  • 6mm
  • Abdomen, thighs, arms
  • 5–7 days
  • Moderate (±18%)
  • Daily dosing requires aggressive 8–12 site rotation; thigh absorption slower but more predictable
  • BPC-157, TB-500 (Healing Peptides)
  • 6–8mm
  • Near injury site (local), abdomen (systemic)
  • 3–5 days for local; 7 days for systemic
  • High (±25%) local effect
  • Local injection concentrates peptide at injury; systemic absorption less critical; rotate locally within 3-inch injury radius
  • Melanotan II, PT-141
  • 48 hours minimum
  • Low (±10%)
  • Short half-life allows same-site re-injection after 48 hours if no visible trauma; still recommend 4-site minimum rotation
  • Cognitive Function Peptides (Semax, Selank)
  • Intranasal or 4mm subQ
  • Abdomen if subQ
  • 7 days if subQ
  • N/A for intranasal
  • Intranasal formulations bypass injection site rotation entirely; subQ formulations rare but follow standard rotation
  • Bottom Line / Professional Assessment
  • Shorter needles (4–6mm) reduce trauma and allow tighter rotation spacing; longer needles (6–8mm) required for thicker tissue but mandate wider spacing and longer rest intervals
  • Abdomen offers highest consistency for systemic peptides; local injury-site injection appropriate only for healing peptides with documented local mechanism
  • 7-day minimum is clinical standard; shorter intervals acceptable only for low-volume, low-frequency peptides with <48hr half-lives
  • Absorption variability increases with decreasing tissue vascularity; monitor response and adjust zones if peptide effect becomes inconsistent across injection cycles
  • Lipohypertrophy risk scales with injection frequency and volume; daily high-volume protocols (>0.5mL) require documented rotation logs to prevent tissue damage